Commercial influences on patient and public involvement: a renewed call for research and action
Patient and public involvement is increasingly advocated in health policy, research and
practice. Patients and people with lived experience, carers and the general public should …
practice. Patients and people with lived experience, carers and the general public should …
What did the scientific literature learn from internal company documents in the pharmaceutical industry? A sco** review
MA Gagnon, M Dong - Cochrane Evidence Synthesis and …, 2023 - Wiley Online Library
Objective To identify all scientific papers that used internal industry documents in the
pharmaceutical sector and analyze what and how the scientific literature learned about …
pharmaceutical sector and analyze what and how the scientific literature learned about …
The interrelation of scientific, ethical, and translational challenges for precision medicine with multimodal biomarkers–A qualitative expert interview study in …
This qualitative study examines the impact of scientific, ethical, and translational challenges
of precision medicine for atopic dermatitis and psoriasis. The study explores how these …
of precision medicine for atopic dermatitis and psoriasis. The study explores how these …
A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups
Our objective was to examine conflicts of interest between the UK's health-focused All-Party
Parliamentary Groups (APPGs) and the pharmaceutical industry between 2012 and 2018 …
Parliamentary Groups (APPGs) and the pharmaceutical industry between 2012 and 2018 …
Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs
Background Many patient organisations collaborate with drug companies, resulting in
concerns about commercial agendas influencing patient advocacy. We contribute to an …
concerns about commercial agendas influencing patient advocacy. We contribute to an …
A 'patient–industry complex'? Investigating the financial dependency of UK patient organisations on drug company funding
We examined the minimum extent of dependency of UK patient organisations on
pharmaceutical industry funding using drug company disclosure reports and patient …
pharmaceutical industry funding using drug company disclosure reports and patient …
Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence
Objectives To assess the relationship between UK-based patient organisation funding and
companies' commercial interests in rare and non-rare diseases in 2020. Design …
companies' commercial interests in rare and non-rare diseases in 2020. Design …
[HTML][HTML] Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
Pharmaceutical industry funding of patient organizations raises ethical challenges related to
patient engagement in healthcare due to fears of commercial agendas influencing patient …
patient engagement in healthcare due to fears of commercial agendas influencing patient …
Philanthropic drug development: understanding its importance, mechanisms, and future prospects
M Reichel, EM Murauer, M Steiner, C Coch… - Drug Discovery …, 2025 - Elsevier
Philanthropic drug development (PDD) addresses gaps in traditional pharmaceutical
innovation, particularly for rare and underserved diseases. Cost and timeline challenges …
innovation, particularly for rare and underserved diseases. Cost and timeline challenges …
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)
Objectives To examine the under-reporting of pharmaceutical company payments to patient
organisations by donors and recipients. Design Comparative descriptive analysis of …
organisations by donors and recipients. Design Comparative descriptive analysis of …